Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05320640
- Locations
- 🇨🇳
Biotherapeutic Department, Chinese PLA General Hospital, Beijing, Beijing, China
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT05222984
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT05201066
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Uni of Massachusetts Medical Center, Worcester, Massachusetts, United States
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 85
- Registration Number
- NCT05184842
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT05038592
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Takeda
- Registration Number
- NCT04985656
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2021-06-30
- Target Recruit Count
- 100
- Registration Number
- NCT04945096
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Brian Jonas
- Target Recruit Count
- 20
- Registration Number
- NCT04905810
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸UCSF-Fresno, Clovis, California, United States
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Foghorn Therapeutics Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT04891757
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
- Conditions
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 39
- Registration Number
- NCT04878432
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸University Hospitals Of Cleveland, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.